Gout and pseudogout: Difference between revisions
| Line 28: | Line 28: | ||
##Options: | ##Options: | ||
###Indomethacin 50mg po TID x3-5d, OR | ###Indomethacin 50mg po TID x3-5d, OR | ||
###Naproxen 500mg po BID x3-7d, OR | |||
###Ibuprofen 800mg PO TID x 3-5d | ###Ibuprofen 800mg PO TID x 3-5d | ||
#NSAIDs contra-indicated | #NSAIDs contra-indicated | ||
| Line 33: | Line 34: | ||
###Can be used as alternative agent to NSAIDs in pt w/ normal renal/hepatic function | ###Can be used as alternative agent to NSAIDs in pt w/ normal renal/hepatic function | ||
###1.2mg PO (load), followed by 0.6mg one hour later x 1 <ref>Terkeltaub RA et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060.</ref> | ###1.2mg PO (load), followed by 0.6mg one hour later x 1 <ref>Terkeltaub RA et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060.</ref> | ||
###Renal impairment not absolute contraindication for acute flare but may consider dose reduction. | |||
###Dose adjustments for CYP3A4 inhibitors (HARRT, Calcium Channel Blockers, fluconazole, erythromycin, clarithromycin) | |||
###Colchicine should not be administered intravenously | ###Colchicine should not be administered intravenously | ||
##Steroids | ##Steroids | ||
Revision as of 00:02, 2 July 2014
Pathophysiology
- Primarily an illness of middle-aged and elderly adults
- Gout is most common form of inflammatory joint disease in men >40yr
- Presence of crystals does not exclude septic arthritis
- Precipitants
- Trauma
- Surgery
- Significant illness
- Change in medication
Clinical Features
- Joint pain may develop over period of hours
- Primarily involves first MTP, knee, ankle
Diagnosis
- Synovial fluid aspiration
- Gout: monosodium urate negative Negatively birefringent
- Pseudogout: calcium pyrophosphate positive birefringence crystals
- Serum uric acid levels are not helpful (30% of pts w/ gout attack have normal levels)
- ESR may be elevated
- no bacteria on Gram Stain
Treatment
- NSAIDs NOT contra-indicated
- Do not give to pts w/ renal insufficiency (use opioids instead)
- Substantial pain relief should occur within 2hr
- Options:
- Indomethacin 50mg po TID x3-5d, OR
- Naproxen 500mg po BID x3-7d, OR
- Ibuprofen 800mg PO TID x 3-5d
- NSAIDs contra-indicated
- Colchicine
- Can be used as alternative agent to NSAIDs in pt w/ normal renal/hepatic function
- 1.2mg PO (load), followed by 0.6mg one hour later x 1 [1]
- Renal impairment not absolute contraindication for acute flare but may consider dose reduction.
- Dose adjustments for CYP3A4 inhibitors (HARRT, Calcium Channel Blockers, fluconazole, erythromycin, clarithromycin)
- Colchicine should not be administered intravenously
- Steroids
- Colchicine
- All patients
- Hold diuretics
- Start losaran to replace diuretic (has modest uricosuric effect)
- Alcohol and dietary counseling
- Continue uric acid-lowering agents if already on prophylactic regimen (do not start)
- Follow up with rheumatoloty
- Glucocorticoid injection
- Even if gout has been diagnosed in the past, be cautious with glucocorticoid joint injection if the current clinical picture is uncertain since a septic joint can coexist with gout.
- Hold diuretics
See Also
Source
- Tintinalli - Gout
- ↑ Terkeltaub RA et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060.
- ↑ Groff GD et al. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum. 1990;19(6):329
- ↑ Janssens H. et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371(9627):1854.
